Rise Advisors’s Caribou Biosciences CRBU Stock Holding History

Rise Advisors’s Portfolio CRBU Stock Details CRBU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-548	Closed	-$1.28K	–	398
2025 Q3	$1.28K	Hold	548	–	–	﹤0.01%	1243
2025 Q2	$690	Buy	+548	New	+$539	﹤0.01%	1350

Other funds holding CRBU

Pfizer New York $239M AUM 232.47% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Rise Advisors's CRBU Position: Q4 2025 in Review

Rise Advisors sold out of Caribou Biosciences (CRBU) in Q4 2025, closing a stake of 548 shares — an estimated $1.28K sold.

Rise Advisors first reported a position in CRBU in Q2 2025 and held it in 2 quarters. The position peaked at $1.28K in Q3 2025. 124 funds tracked by Wall St. Rank hold CRBU as of Q4 2025.

Rise Advisors reported no remaining Caribou Biosciences position as of Q4 2025 after selling out during the quarter.
Rise Advisors sold 548 Caribou Biosciences shares in Q4 2025, an estimated $1.28K.
Rise Advisors first reported a position in Caribou Biosciences in Q2 2025 and held it in 2 quarters.
Rise Advisors's Caribou Biosciences position peaked at $1.28K in Q3 2025.
124 funds tracked by Wall St. Rank held Caribou Biosciences as of Q4 2025.

Based on Rise Advisors's 13F filing for Q4 2025, filed 11 Feb 2026.